Researchers used precancerous breast cells from patients with Li-Fraumeni syndrome to test the effectiveness of chemopreventive agents in preventing cancer. Treatment with tamoxifen, a p53-rescue drug, and PPAR-ã agonist showed promise in stopping cancer development, suggesting new potential therapies for high-risk individuals.
Researchers discovered that telomere shortening is a common feature in high-grade prostatic intraepithelial neoplasia (HGPIN), the precursor to prostate cancer. Shortened telomeres were found in 93% of HGPIN lesions, suggesting their role as potential biomarkers for early detection and prevention.
Researchers have found that topical retinoids, such as tazarotene, may be a safer alternative for preventing skin cancer in individuals at risk. The study used mice with basal cell nevus syndrome, a genetic disorder that predisposes them to developing large numbers of basal cell carcinomas.
The American Association for Cancer Research (AACR) is calling on the FDA to accelerate the development and approval of chemopreventive agents for precancerous cells. Emerging technologies have improved detection capabilities, but drug approvals remain limited due to concerns about treatment efficacy in high-risk populations.
Researchers discovered deguelin's ability to selectively block the growth of precancerous and cancerous human bronchial epithelial cells. The study suggests deguelin may inhibit Akt activation, a critical cell survival signal for tumor progression.
Daily estradiol treatment for three weeks reduces mammary cancer incidence by 90% in rats. The study suggests a simple and safe hormonal prevention method for human breast cancer, comparable to full-term pregnancy or tamoxifen treatment.
A study published in Cancer Research found that COX-2 inhibitors, such as celecoxib, can delay the onset of breast cancer in genetically bred HER-2/neu mice. The mice treated with celecoxib experienced a significant reduction in tumor incidence and a longer time to disease progression compared to control mice.
Research suggests that moderate to high levels of maternal alcohol consumption during pregnancy can lead to increased estrogen levels in the fetus. As a result, female offspring are more likely to develop breast tumors later in life.
Studies suggest that moderate dietary restriction, exercise, and healthy diet rich in omega-3 fatty acids can delay breast cancer growth and reduce risk. Calorie restriction is effective in both spontaneous and chemically induced rodent tumor models, but may have adverse effects on bone density.
Dr. Michael Sporn, a renowned cancer researcher, has made significant contributions to cancer prevention through his work on chemoprevention and the development of new strategies to reduce cancer incidence and death. He is recognized for his pioneering studies on the role of Vitamin A and retinoids in cancer prevention.
Researchers developed a Herceptin-DM1 conjugate that targets HER2-positive breast cancer and shows complete regression in mice. Additionally, a new Bcr-Abl inhibitor called PD173955 demonstrates greater potency than Gleevec against leukemia cells, providing new hope for treatment-resistant cancers.
A long duration of regular aspirin use is associated with a significant increase in pancreatic cancer risk among women. Women taking 14 or more tablets per week experience nearly an 86% increased risk, while those taking six to 13 tablets per week see a 41% higher risk.